Design: Two-group randomized click here trial.
Setting: Twelve methadone maintenance clinics with on-site HIV care in the Bronx, New York.
Participants: HIV-infected adults prescribed combination antiretroviral therapy.
Main outcomes measures: Between group differences at four assessment points from baseline to week 24 in: (1) antiretroviral adherence
measured by pill count, (2) VL, and (3) proportion with undetectable VI. (<75 copies/ml).
Results: Between June 2004 and August 2007, we enrolled 77 participants. Adherence in the DOT group was higher than in the control group at all post-baseline assessment points; by week 24 mean DOT adherence was 86% compared to 56% in the control group (p<0.0001). Group differences in mean adherence remained significant after stratifying by baseline VL (detectable versus undetectable). In addition, during the 24-week intervention, the proportion of DOT participants with undetectable VL increased
from 51% to 71%.
Conclusions: Among HIV-infected opioid users, antiretroviral DOT administered in methadone clinics was efficacious for improving adherence and decreasing VL, and these improvements were maintained over a 24-week period. DOT should be more widely available to methadone patients. (C) 2010 Elsevier Ireland Ltd. All rights reserved.”
“The traditional PVA-boric acid method BEZ235 was modified using calcium carbonate as a pore-forming agent to form the macroporous structure and formulated macroporous carrier (MPC) post-crosslinked with glutaraldehyde. The pore volumes, pore structure, porosity, and swelling behavior of MPCs were evaluated. The crosslinking density of MPCs with four different crosslinker dosages was
calculated from their swelling properties using the modified Flory equation. MPCs demonstrated high swelling capacity, large specific surface area, high diffusion coefficient, as well as chemical and mechanical strength. The high crosslinking degree MPCs resulted in high biomass densities and low activity yield and vice versa. The characterizations of MPC suggest significant potential of its use for microbial immobilization and provide a scientific basis for immobilized carrier design and optimization. (C) 2010 Elsevier B.V. PF-6463922 manufacturer All rights reserved.”
“BACKGROUND: Pandemic 2009 H1N1 influenza virus (H1N1) infection is considered harmful to lung transplant recipients (LTRs). Vaccination against this virus is recommended for LTRs, but little is known about associated benefits and risks. Our aim in this study is to document the safety and clinical effectiveness of the HI NI vaccine in LTRs.
METHODS: All LTRs received an informational letter on the H1N1 pandemic that included hygiene and vaccination recommendations. After completing a questionnaire, volunteering LTRs received Pandemrix (H1N1 2009 Monovalent AS03-Adjuvanted Vaccine; GSK).